Ones To Watch News
Refine Search
Pharmaceutical
Switzerland-based Arvelle Therapeutics, which was acquired by Italy’s Angelini earlier this year, today announced that it has received a positive Final Appraisal Determination (FAD) from the National Institute for Health and Clinical Excellence (NICE) for Ontozry (cenobamate). 15 November 2021
Biotechnology
The US Food and Drug Administration on Friday approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells. 13 November 2021
Biotechnology
French rare diseases company Dynacure has entered a long-term strategic development and commercialization agreement with Japanese drugmaker Nippon Shinyaku. 11 November 2021
Biotechnology
USA-based Finch Therapeutics, a specialist in oral biologics, today announced positive top-line results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase II placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI). 10 November 2021
Biotechnology
UK ophthalmology focussed gene therapy company Gyroscope Therapeutics says that French pharms major Sanofi has committed to invest up to $60.0 million (£44.5 million) in equity in Gyroscope. 10 November 2021
Pharmaceutical
In what is a late entry into the competitive migraine therapy sector, Pfizer has signed strategic commercialization arrangement for Biohaven Pharmaceutical’s rimegepant in markets outside of the USA upon approval. 10 November 2021
Biotechnology
Marking a second licensing deal signed today by China’s Zai Lab, it has entered into a collaboration with US precision cancer therapy specialist Blueprint Medicines. 9 November 2021
Biotechnology
Shares of US biotech Karuna Therapeutics were down as much as 2% in early trading, despite the fact that it has entered into an exclusive license agreement with Shanghai, China-based Zai Lab for the development, manufacturing and commercialization of KarXT in Greater China, including mainland China, Hong Kong, Taiwan and Macau. 9 November 2021
Biotechnology
Mirati Therapeutics has announced that the US Food and Drug Administration will review the company's New Drug Application (NDA) for adagrasib for the treatment of patients with previously treated KRASG12C-mutated non-small cell lung cancer (NSCLC) who have received prior systemic therapy under the Real-Time Oncology Review (RTOR) pilot program. 9 November 2021
Biotechnology
UK-headquartered cancer immunotherapy company Autolus Therapeutics and Blackstone Life Sciences today announced that they have entered into a strategic collaboration and financing agreement. 8 November 2021
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals saw its shares plummet more than 74% to $9.21 on Friday, after it announced top-line results from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib, which did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib. 6 November 2021
Biotechnology
US CNS-focussed drug biotech Amylyx Pharmaceuticals says it has now submitted a New Drug Application (NDA) to the US Food and Drug Administration for AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). 3 November 2021
Biotechnology
The US Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. 2 November 2021
Pharmaceutical
US antibacterial and antiviral drug R&D firm Venatorx Pharmaceutical has entered into a research collaboration and license agreement with Swiss pharma giant Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (PBPs) in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales (CRE). 2 November 2021
Biotechnology
Japanese biotech start-up Aculys Pharma today announced the closing of a $60 million Series A financing led by SoftBank Vision Fund 2 and joined by Catalys Pacific, HBM Healthcare Investments, Global Founders Capital, Sumitomo Mitsui Trust Investment, and ANRI. 1 November 2021
Biotechnology
Market reaction was positive for Immutep, with the Australian biotech announcing progress for its lead candidate, a novel LAG-3 related immunotherapy treatment for cancer and autoimmune disease, with its shares rising 2.6% to A$0.58. 1 November 2021
Biotechnology
Following the announcement that its Phase III TRYbeCA-1 clinical trials of eryaspase in 512 second-line patients with metastatic pancreatic cancer failed to meet its primary endpoint, shares of Lyon, France-based biotech firm Erytech Pharma plummeted as much as 40%. 28 October 2021
Biotechnology
Now three years since its founding, US biotech Mammoth Biosciences, which is building the next generation of CRISPR products to cure and detect disease, has signed its first major R&D deal. 26 October 2021
Biotechnology
US a multi-asset longevity biotech Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. 26 October 2021
Pharmaceutical
Austrian drug developer Marinomed Biotech has entered a new collaboration and licensing agreement with Chinese drugmaker Luoxin Pharmaceutical Group. 21 October 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze